Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Endocrine disorders – page 18

  • 497 clinical trials
  • 183 recruiting
  • 211 conditions
  • 25 countries

Conditions in this area

211 conditions with trials, the busiest first

Type 2 diabetes mellitus83Type 1 diabetes mellitus38Endocrine ophthalmopathy26Neuroblastoma26Obesity22Diabetes mellitus21Neuroendocrine tumour19Gastroenteropancreatic neuroendocrine tumour disease16Overweight16Diabetic foot13Diabetic retinal oedema13Diabetic neuropathy12Myotonic dystrophy12Adrenogenital syndrome11Neuroendocrine carcinoma11Thyroid cancer11Graves' disease10Hypoparathyroidism9Acromegaly8Chronic kidney disease8Adrenoleukodystrophy7Glucose tolerance impaired7Pancreatic neuroendocrine tumour7Adrenocortical carcinoma6+187

Clinical trials in Endocrine disorders

497 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

497 clinical trials

Diabetes mellitus

Not yet recruiting

Effect of liraglutide on immune response to pneumococcal polysaccharide vaccine in adults with diabetes

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Liraglutide
  • Sponsor:Stichting Radboud University Medical Center

Pituitary tumour benign

Not yet recruiting

Fluoroethyltyrosine F-18 PET Scan for Adults with Suspected Functional Pituitary Adenoma and Unclear MRI Results

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluoroethyltyrosine F-18
  • Sponsor:Centre Hospitalier Universitaire De Lille

Thyroid cancer+1

Not yet recruiting

Study of levothyroxine sodium plus liothyronine sodium vs levothyroxine sodium to control TSH in advanced thyroid cancer patients on tyrosine kinase inhibitors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Levothyroxine Sodium

Type 2 diabetes mellitus

Not yet recruiting

Effect of dapagliflozin and semaglutide on heart insulin resistance in type 2 diabetes patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Pancreatic neuroendocrine tumour

Not yet recruiting

Randomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Institut Gustave Roussy

Neuroendocrine tumour

Not yet recruiting

Evaluation of V-Cu64 versus V-Ga68 PET-CT imaging in adults with diagnosed or suspected neuroendocrine tumors

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Edotreotide

Gastroenteropancreatic neuroendocrine tumour disease

Not yet recruiting

68Ga-DOTATATE PET/CT Prognostic Assessment in Patients with Well-Differentiated Grade 2 Gastroenteropancreatic Neuroendocrine Tumors Treated with 177Lu-oxodotreotide and Edotreotide

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Edotreotide
  • Sponsor:Centre De Lutte Contre Le Cancer Eugene Marquis

Type 2 diabetes mellitus+2

Not yet recruiting

Effect of semaglutide, acetylsalicylic acid, and clopidogrel on blood clotting in patients with diabetes or overweight with cardiovascular disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid

Type 2 diabetes mellitus

Not yet recruiting

A study to evaluate the effectiveness of NNC0662-0419 and semaglutide in people with type 2 diabetes

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · Healthy volunteers
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Hypoparathyroidism

Not yet recruiting

Study evaluating the effects of palopegteriparatide and alfacalcidol on quality of life and brain function in patients with hypoparathyroidism

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Alfacalcidol
  • Sponsor:Region Midtjylland

Diabetic foot+1

Not yet recruiting

Comparing local gentamicin or vancomycin hydrochloride to a drug combination for patients with diabetic foot osteomyelitis

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Pirkanmaan hyvinvointialue

Type 1 diabetes mellitus

Not yet recruiting

Study of the efficacy and safety of ladarixin and rabbit anti-human thymocyte immunoglobulin in adolescents and adults with new-onset type 1 diabetes

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Ladarixin
  • Sponsor:Ospedale San Raffaele S.r.l.

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Semaglutide46 clinical trialsDapagliflozin21 clinical trialsEmpagliflozin14 clinical trialsSodium Chloride13 clinical trialsCisplatin12 clinical trialsEtoposide12 clinical trialsMetformin Hydrochloride12 clinical trialsCarboplatin11 clinical trialsInsulin Glargine11 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.